Patents by Inventor Joerg Hoernschemeyer

Joerg Hoernschemeyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF
    Publication number: 20230127248
    Abstract: Aqueous pharmaceutical formulations, for parenteral administration, comprising peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof wherein the peptidomimetic macrocycle binds to MDM2 and/or MDMX proteins are disclosed. Also disclosed are methods of treating diseases and disorders using the aqueous pharmaceutical formulations disclosed herein.
    Type: Application
    Filed: June 16, 2022
    Publication date: April 27, 2023
    Inventors: David Allen ANNIS, Krzysztof DARLAK, Chris RHODES, Sonoko KANAI, Joerg HOERNSCHEMEYER, Michaela GRASS
  • LNA-G process
    Patent number: 11591594
    Abstract: Recent advancements in LNA oligonucleotides include the use of amine linkers to link an LNA antisense oligonucleotide to a conjugate group. For example please see WO2014/I18267. The present invention originates from the identification of a problem when de-protecting LNA oligonucleotides which comprise an aliphatic amine group and DMF protected LNA G nucleoside, which results in the production of a +28 Da impurity. This problem is solved by using acyl protection groups on the exocyclic nitrogen of the LNA-G residue, rather than the standard DMF protection group.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: February 28, 2023
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Dennis Jul Hansen, Joerg Hoernschemeyer, Jacob Ravn, Christoph Rosenbohm
  • Novel Process for Preparing Rhenium Chelated MAG3 Oligonucleotides
    Publication number: 20220194972
    Abstract: The present invention relates to a novel process for preparing a compound of formula (III) and rhenium chelated MAG3 oligonucleotides.
    Type: Application
    Filed: April 28, 2020
    Publication date: June 23, 2022
    Inventors: Dennis Jul Hansen, Erik Daa Funder, Joerg Hoernschemeyer
  • PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF
    Publication number: 20210299211
    Abstract: Aqueous pharmaceutical formulations, for parenteral administration, comprising peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof wherein the peptidomimetic macrocycle binds to MDM2 and/or MDMX proteins are disclosed. Also disclosed are methods of treating diseases and disorders using the aqueous pharmaceutical formulations disclosed herein.
    Type: Application
    Filed: November 6, 2020
    Publication date: September 30, 2021
    Inventors: David Allen Annis, Krzysztof Darlak, Chris Rhodes, Sonoko Kanai, Joerg Hoernschemeyer, Michaela Grass
  • Peptidomimetic macrocycles and formulations thereof
    Patent number: 10905739
    Abstract: Aqueous pharmaceutical formulations, for parenteral administration, comprising peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof wherein the peptidomimetic macrocycle binds to MDM2 and/or MDMX proteins are disclosed. Also disclosed are methods of treating diseases and disorders using the aqueous pharmaceutical formulations disclosed herein.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: February 2, 2021
    Assignee: Aileron Therapeutics, Inc.
    Inventors: David Allen Annis, Krzysztof Darlak, Chris Rhodes, Sonoko Kanai, Joerg Hoernschemeyer, Michaela Grass
  • LNA-G Process
    Publication number: 20200318109
    Abstract: Recent advancements in LNA oligonucleotides include the use of amine linkers to link an LNA antisense oligonucleotide to a conjugate group. For example please see WO2014/I 18267. The present invention originates from the identification of a problem when de-protecting LNA oligonucleotides which comprise an aliphatic amine group and DMF protected LNA G nucleoside, which results in the production of a +28 Da impurity. This problem is solved by using acyl protection groups on the exocyclic nitrogen of the LNA-G residue, rather than the standard DMF protection group.
    Type: Application
    Filed: March 6, 2020
    Publication date: October 8, 2020
    Inventors: Dennis Jul Hansen, Joerg Hoernschemeyer, Jacob Ravn, Christoph Rosenbohm
  • LNA-G Process
    Publication number: 20190055550
    Abstract: Recent advancements in LNA oligonucleotides include the use of amine linkers to link an LNA antisense oligonucleotide to a conjugate group. For example please see WO2014/118267. The present invention originates from the identification of a problem when de-protecting LNA oligonucleotides which comprise an aliphatic amine group and DMF protected LNA G nucleoside, which results in the production of a +28 Da impurity. This problem is solved by using acyl protection groups on the exocyclic nitrogen of the LNA-G residue, rather than the standard DMF protection group.
    Type: Application
    Filed: August 22, 2016
    Publication date: February 21, 2019
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Dennis Jul Hansen, Joerg Hoernschemeyer, Jacob Ravn, Christoph Rosenbohm
  • PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF
    Publication number: 20160101145
    Abstract: Aqueous pharmaceutical formulations, for parenteral administration, comprising peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof wherein the peptidomimetic macrocycle binds to MDM2 and/or MDMX proteins are disclosed. Also disclosed are methods of treating diseases and disorders using the aqueous pharmaceutical formulations disclosed herein.
    Type: Application
    Filed: September 24, 2015
    Publication date: April 14, 2016
    Inventors: David Allen Annis, Krzysztof Darlak, Chris Rhodes, Sonoko Kanai, Joerg Hoernschemeyer, Michaela Grass